SDT-102

Dose escalation phase (applicable to Phase Ia) Main purpose To evaluate the safety and tolerability of oral SDT-102 tablets in patients with relapsed/refractory hematological malignancies; To explore the dose limiting toxicity (DLT), maximum tolerated dose (MTD), and recommended phase 2 dose (RP2D) of SDT-102 tablets in patients with relapsed/refractory hematological malignancies. Secondary purpose To evaluate the pharmacokinetic (PK) characteristics of SDT-102 after taking the drug in patients with relapsed/refractory hematological malignancies; To evaluate the preliminary efficacy of oral SDT-102 tablets in patients with relapsed/refractory hematological malignancies (ORR, PFS, DCR, with ORR as the primary observation index). Dose expansion phase (applicable to Phase Ib) Main purpose Further evaluate and verify the safety and preliminary efficacy (ORR, PFS, DCR, with ORR as the primary outcome measure) of oral administration of SDT-102 tablets in patients with specific relapsed/refractory hematological malignancies at the RP2D dose; Secondary purpose Further evaluate and verify the PK characteristics of oral administration of SDT-102 tablets in patients with relapsed/refractory hematological malignancies at the RP2D dose.